Daxor(US:DXR) Globenewswireยท2025-09-02 12:00Core Insights - Daxor Corporation has achieved significant milestones in 2025, including FDA clearance for a new rapid Blood Volume Analysis (BVA) system, marking a transformative moment for the company [4][8] - The company reported a 73% increase in unaudited revenues for the first half of 2025 compared to the same period in 2024, driven by sales of diagnostic kits and military contracts [6][8] - Daxor's net asset value increased to $36.6 million as of June 30, 2025, reflecting a $3.97 million increase from the previous year [6][8] Product Innovation - The new BVA system is three times faster, portable, and smaller than the existing BVA-100, while maintaining the ability to measure total blood volume, red blood cell volume, plasma volume, and albumin transudation rate [4][8] - The company is committed to rolling out the new BVA system and accelerating commercial operations alongside ongoing research and development for additional products [8] Financial Performance - Daxor's operating division reported a significant revenue increase, with net asset value per share rising to $7.15, up $0.40 from the previous year [6][8] - The company experienced a net decrease in unrealized appreciation on investments but reported net realized gains of $468,212 for the first half of 2025 [6] Market Adoption and Clinical Validation - The adoption of Daxor's BVA technology has accelerated, with new accounts contributing to revenue growth and clinical acceptance [6][8] - A significant study published in the American Heart Journal highlighted the utility of BVA technology in managing heart failure, showing that patients identified as euvolemic had 2.61 times better survival rates [9] Industry Engagement - Daxor actively engaged with the medical community through industry events to showcase its technology and foster awareness among cardiovascular professionals [7][9] - The company exhibited at major conferences, further solidifying its presence in the healthcare sector [9]